Osteopontin—a master regulator of epithelial-mesenchymal transition

Journal of Clinical Medicine

Volumn 5, Issue 4, 2016, Pages

  Kothari, Anai N ^a,b   Arffa, Matthew L ^a   Chang, Victor ^a   Blackwell, Robert H ^a   Syn, Wing Kin ^c   Zhang, Jiwang ^a   Mi, Zhiyong ^a   Kuo, Paul C ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cancer associated fibroblasts; Epithelial mesenchymal transition; Fibrosis; Osteopontin; Tumor metastasis; Tumor microenvironment

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; OSTEOPONTIN; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN;

BREAST CANCER; COLORECTAL CANCER; DROSOPHILA MELANOGASTER; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL; MYOFIBROBLAST; NONHUMAN; OVARY CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 85048751041     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5040039     Document Type: Review

References (114)

1. Senger, D.R.; Wirth, D.F.; Hynes, R.O. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979, 16, 885-893. [CrossRef]
2. Denhardt, D.T.; Guo, X. Osteopontin: A protein with diverse functions. FASEB J. 1993, 7, 1475-1482. [PubMed]
3. Wai, P.Y.; Kuo, P.C. Osteopontin: Regulation in tumor metastasis. Cancer Metastasis Rev. 2008, 27, 103-118. [CrossRef] [PubMed]
4. Lund, S.A.; Giachelli, C.M.; Scatena, M. The role of osteopontin in inflammatory processes. J. Cell Commun. Signal. 2009, 3, 311-322. [CrossRef] [PubMed]
5. Weber, C.E.; Li, N.Y.; Wai, P.Y.; Kuo, P.C. Epithelial-mesenchymal transition, TGF-beta, and osteopontin in wound healing and tissue remodeling after injury. J. Burn Care Res. 2012, 33, 311-318. [CrossRef] [PubMed]
6. Wai, P.Y.; Kuo, P.C. The role of osteopontin in tumor metastasis. J. Surg. Res. 2004, 121, 228-241. [CrossRef] [PubMed]
7. Pritchett, J.; Harvey, E.; Athwal, V.; Berry, A.; Rowe, C.; Oakley, F.; Moles, A.; Mann, D.A.; Bobola, N.; Sharrocks, A.D. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012, 56, 1108-1116. [CrossRef] [PubMed]
8. Tan, T.K.; Zheng, G.; Hsu, T.; Lee, S.R.; Zhang, J.; Zhao, Y.; Tian, X.; Wang, Y.; Wang, Y.M.; Cao, Q. Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage. Laboratory Investig. 2013, 93, 434-449. [CrossRef] [PubMed]
9. Chen, C.; Li, R.; Ross, R.S.; Manso, A.M. Integrins and integrin-related proteins in cardiac fibrosis. J. Mol. Cell Cardiol. 2015. [CrossRef] [PubMed]
10. Cao, D.; Li, Z.; Jiang, X.; Lum, Y.L.; Khin, E.; Lee, N.P.; Wu, G.; Luk, J.M. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J. Gastroenterol. 2012, 18, 3923. [CrossRef] [PubMed]
11. Huang, J.; Pan, C.; Hu, H.; Zheng, S.; Ding, L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS ONE 2012, 7, e47901. [CrossRef] [PubMed]
12. Hay, E. An overview of epithelio-mesenchymal transformation. Cells Tissues Organs (Print) 1995, 154, 8-20. [CrossRef]
13. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420-1428. [CrossRef] [PubMed]
14. Kalluri, R. EMT: When epithelial cells decide to become mesenchymal-like cells. J. Clin. Investig. 2009, 119, 1417-1419. [CrossRef] [PubMed]
15. Huber, M.A.; Kraut, N.; Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17, 548-558. [CrossRef] [PubMed]
16. Savagner, P. Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23, 912-923. [CrossRef] [PubMed]
17. Seton-Rogers, S. Epithelial-mesenchymal transition: Untangling EMT's functions. Nat. Rev. Cancer 2016, 16. [CrossRef] [PubMed]
18. Kang, Y.; Massagué, J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004, 118, 277-279. [CrossRef] [PubMed]
19. Ansieau, S.; Morel, A.; Hinkal, G.; Bastid, J.; Puisieux, A. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010, 29, 3173-3184. [CrossRef] [PubMed]
20. Maestro, R.; Dei Tos, A.P.; Hamamori, Y.; Krasnokutsky, S.; Sartorelli, V.; Kedes, L.; Doglioni, C.; Beach, D.H.; Hannon, G.J. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999, 13, 2207-2217. [CrossRef] [PubMed]
21. Beck, B.; Lapouge, G.; Rorive, S.; Drogat, B.; Desaedelaere, K.; Delafaille, S.; Dubois, C.; Salmon, I.; Willekens, K.; Marine, J. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 2015, 16, 67-79. [CrossRef] [PubMed]
22. Elias, M.C.; Tozer, K.R.; Silber, J.R.; Mikheeva, S.; Deng, M.; Morrison, R.S.; Manning, T.C.; Silbergeld, D.L.; Glackin, C.A.; Reh, T.A. TWIST is expressed in human gliomas, promotes invasion. Neoplasia 2005, 7, 824-837. [CrossRef] [PubMed]
23. Hasselblatt, M.; Mertsch, S.; Koos, B.; Riesmeier, B.; Stegemann, H.; Jeibmann, A.; Tomm, M.; Schmitz, N.; Wrede, B.; Wolff, J.E.; et al. TWIST-1 is overexpressed in neoplastic choroid plexus epithelial cells and promotes proliferation and invasion. Cancer Res. 2009, 69, 2219-2223. [CrossRef] [PubMed]
24. Lee, T.K.; Poon, R.T.; Yuen, A.P.; Ling, M.T.; Kwok, W.K.; Wang, X.H.; Wong, Y.C.; Guan, X.Y.; Man, K.; Chau, K.L.; et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res. 2006, 12, 5369-5376. [CrossRef] [PubMed]
25. Yang, J.; Mani, S.A.; Donaher, J.L.; Ramaswamy, S.; Itzykson, R.A.; Come, C.; Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117, 927-939. [CrossRef] [PubMed]
26. Yuen, H.F.; Chan, Y.P.; Wong, M.L.; Kwok, W.K.; Chan, K.K.; Lee, P.Y.; Srivastava, G.; Law, S.Y.; Wong, Y.C.; Wang, X.; et al. Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J. Clin. Pathol. 2007, 60, 510-514. [CrossRef] [PubMed]
27. Yao, C.; Li, P.; Song, H.; Song, F.; Qu, Y.; Ma, X.; Shi, R.; Wu, J. CXCL12/CXCR4 axis upregulates twist to induce EMT in human glioblastoma. Mol. Neurobiol. 2015. [CrossRef] [PubMed]
28. Vesuna, F.; Lisok, A.; Kimble, B.; Raman, V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009, 11, 1318-1328. [CrossRef] [PubMed]
29. Yin, G.; Chen, R.; Alvero, A.B.; Fu, H.; Holmberg, J.; Glackin, C.; Rutherford, T.; Mor, G. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010, 29, 3545-3553. [CrossRef] [PubMed]
30. Lee, M.; Lowe, G.N.; Strong, D.D.; Wergedal, J.E.; Glackin, C.A. TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J. Cell. Biochem. 1999, 75, 566-577. [CrossRef]
31. Li, N.Y.; Weber, C.E.; Mi, Z.; Wai, P.Y.; Cuevas, B.D.; Kuo, P.C. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. J. Am. Coll Surg. 2013, 217, 17-26. [CrossRef] [PubMed]
32. Li, N.Y.; Weber, C.E.; Wai, P.Y.; Cuevas, B.D.; Zhang, J.; Kuo, P.C.; Mi, Z. An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines. Surgery 2013, 154, 404-410. [CrossRef] [PubMed]
33. Scimeca, M.; Giannini, E.; Antonacci, C.; Pistolese, C.A.; Spagnoli, L.G.; Bonanno, E. Microcalcifications in breast cancer: An active phenomenon mediated by epithelial cells with mesenchymal characteristics. BMC Cancer 2014, 14. [CrossRef] [PubMed]
34. Hornik, C.; Brand-Saberi, B.; Rudloff, S.; Christ, B.; Füchtbauer, E. Twist is an integrator of SHH, FGF, and BMP signaling. Anat. Embryol. 2004, 209, 31-39. [CrossRef] [PubMed]
35. Dong, Q.; Zhu, X.; Dai, C.; Zhang, X.; Jia, H.; Ye, Q.; Qin, L. Osteopontin regulated epithelial-mesenchymal transition via PI3K/AKT signaling pathway in hepatocellular carcinoma. Cancer Res. 2013, 73, 2695-2695. [CrossRef]
36. Yang, M.; Wu, M.; Chiou, S.; Chen, P.; Chang, S.; Liu, C.; Teng, S.; Wu, K. Direct regulation of TWIST by HIF-1_ promotes metastasis. Nat. Cell Biol. 2008, 10, 295-305. [CrossRef] [PubMed]
37. Song, G.; Cai, Q.; Mao, Y.; Ming, Y.; Bao, S.; Ouyang, G. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1_ expression through the PI3-K/Akt pathway. Cancer Sci. 2008, 99, 1901-1907. [CrossRef] [PubMed]
38. Song, G.; Ouyang, G.; Mao, Y.; Ming, Y.; Bao, S.; Hu, T. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1_ up-regulation and MMP9 activation. J. Cell. Mol. Med. 2009, 13, 1706-1718. [CrossRef] [PubMed]
39. Cao, L.; Fan, X.; Jing, W.; Liang, Y.; Chen, R.; Liu, Y.; Zhu, M.; Jia, R.; Wang, H.; Zhang, X.; et al. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-kappaB-HIF-1alpha pathway. Oncotarget 2015, 6, 6627-6640. [CrossRef] [PubMed]
40. Ng, L.; Wan, T.M.; Lam, C.S.; Chow, A.K.; Wong, S.K.; Man, J.H.; Li, H.; Cheng, N.S.; Pak, R.C.; Cheung, A.H. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS ONE 2015, 10, e0126219. [CrossRef] [PubMed]
41. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Boil. 2014, 15, 178-196. [CrossRef] [PubMed]
42. Zheng, H.; Kang, Y. Multilayer control of the EMT master regulators. Oncogene 2014, 33, 1755-1763. [CrossRef] [PubMed]
43. Postigo, A.A.; Depp, J.L.; Taylor, J.J.; Kroll, K.L. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 2003, 22, 2453-2462. [CrossRef] [PubMed]
44. Vandewalle, C.; Van Roy, F.; Berx, G. The role of the ZEB family of transcription factors in development and disease. Cell. Mol. Life Sci. 2009, 66, 773-787. [CrossRef] [PubMed]
45. Singh, A.B.; Sharma, A.; Smith, J.J.; Krishnan, M.; Chen, X.; Eschrich, S.; Washington, M.K.; Yeatman, T.J.; Beauchamp, R.D.; Dhawan, P. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology 2011, 141, 2140-2153. [CrossRef] [PubMed]
46. Ohashi, S.; Natsuizaka, M.; Wong, G.S.; Michaylira, C.Z.; Grugan, K.D.; Stairs, D.B.; Kalabis, J.; Vega, M.E.; Kalman, R.A.; Nakagawa, M.; et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res. 2010, 70, 4174-4184. [CrossRef] [PubMed]
47. Naganuma, S.; Ohashi, S.; Kimura, S.; Natsuizaka, M.; Gimotty, P.; Klein-Szanto, A.J.; Itoh, H.; Nakagawa, H. ZEB1 and ZEB2 promote EMT and invasion in esophageal squamous cell carcinoma. Cancer Res. 2010, 70, 2293-2293. [CrossRef]
48. Schmalhofer, O.; Brabletz, S.; Brabletz, T. E-cadherin, _-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28, 151-166. [CrossRef] [PubMed]
49. Urtasun, R.; Lopategi, A.; George, J.; Leung, T.; Lu, Y.; Wang, X.; Ge, X.; Fiel, M.I.; Nieto, N. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin _V_3 engagement and PI3K/pAkt/NF_B signaling. Hepatology 2012, 55, 594-608. [CrossRef] [PubMed]
50. Chua, H.; Bhat-Nakshatri, P.; Clare, S.; Morimiya, A.; Badve, S.; Nakshatri, H. NF-_B represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2. Oncogene 2007, 26, 711-724. [CrossRef] [PubMed]
51. Min, C.; Eddy, S.F.; Sherr, D.H.; Sonenshein, G.E. NF-_B and epithelial to mesenchymal transition of cancer. J. Cell. Biochem. 2008, 104, 733-744. [CrossRef] [PubMed]
52. Baud, J.; Varon, C.; Chabas, S.; Chambonnier, L.; Darfeuille, F.; Staedel, C. Helicobacter pylori initiates a mesenchymal transition through ZEB1 in gastric epithelial cells. PLoS ONE 2013, 8, e60315. [CrossRef] [PubMed]
53. Kim, T.; Veronese, A.; Pichiorri, F.; Lee, T.J.; Jeon, Y.J.; Volinia, S.; Pineau, P.; Marchio, A.; Palatini, J.; Suh, S.S.; et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 2011, 208, 875-883. [CrossRef] [PubMed]
54. Cano, A.; Pérez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2, 76-83. [CrossRef] [PubMed]
55. Ikenouchi, J.; Matsuda, M.; Furuse, M.; Tsukita, S. Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci. 2003, 116, 1959-1967. [CrossRef] [PubMed]
56. Gnemmi, V.; Bouillez, A.; Gaudelot, K.; Hémon, B.; Ringot, B.; Pottier, N.; Glowacki, F.; Villers, A.; Vindrieux, D.; Cauffiez, C. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/_-catenin pathway and interaction with SNAIL promoter. Cancer Lett. 2014, 346, 225-236. [CrossRef] [PubMed]
57. Zhu, M.; Yin, F.; Fan, X.; Jing, W.; Chen, R.; Liu, L.; Zhang, L.; Liu, Y.; Liang, Y.; Bu, F. Decreased TIP30 promotes Snail-mediated epithelial-mesenchymal transition and tumor-initiating properties in hepatocellular carcinoma. Oncogene 2015, 34, 1420-1431. [CrossRef] [PubMed]
58. Wang, Y.; Shi, J.; Chai, K.; Ying, X.; Zhou, B.P. The Role of Snail in EMT and Tumorigenesis. Curr. Cancer Drug Targets 2013, 13, 963-972. [CrossRef] [PubMed]
59. Peinado, H.; Olmeda, D.; Cano, A. Snail, ZEB and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat. Rev. Cancer 2007, 7, 415-428. [CrossRef] [PubMed]
60. Bhattacharya, S.D.; Mi, Z.; Kim, V.M.; Guo, H.; Talbot, L.J.; Kuo, P.C. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann. Surg. 2012, 255, 319-325. [CrossRef] [PubMed]
61. Clement, V.; Sanchez, P.; De Tribolet, N.; Radovanovic, I.; i Altaba, A.R. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 2007, 17, 165-172. [CrossRef] [PubMed]
62. Bian, Y.; Huang, S.; Yang, L.; Ma, X.; Xie, J.; Zhang, H. Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J. Gastroenterol. 2007, 13, 1659. [CrossRef] [PubMed]
63. Sanchez, P.; Hernandez, A.M.; Stecca, B.; Kahler, A.J.; DeGueme, A.M.; Barrett, A.; Beyna, M.; Datta, M.W.; Datta, S.; i Altaba, A.R. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc. Natl. Acad. Sci. USA 2004, 101, 12561-12566. [CrossRef] [PubMed]
64. Chou, C.; Lieu, A.; Wu, C.; Chang, L.; Loh, J.; Lin, R.; Chen, W.; Liao, H.; Fu, W.; Chang, C. Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol. Rep. 2010, 24, 1225-1232. [PubMed]
65. Li, X.; Deng, W.; Nail, C.D.; Bailey, S.K.; Kraus, M.H.; Ruppert, J.M.; Lobo-Ruppert, S.M. Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene 2006, 25, 609-621. [CrossRef] [PubMed]
66. Yoon, J.W.; Kita, Y.; Frank, D.J.; Majewski, R.R.; Konicek, B.A.; Nobrega, M.A.; Jacob, H.; Walterhouse, D.; Iannaccone, P. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J. Biol. Chem. 2002, 277, 5548-5555. [CrossRef] [PubMed]
67. Das, S.; Harris, L.G.; Metge, B.J.; Liu, S.; Riker, A.I.; Samant, R.S.; Shevde, L.A. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J. Biol. Chem. 2009, 284, 22888-22897. [CrossRef] [PubMed]
68. Syn, W.; Choi, S.S.; Liaskou, E.; Karaca, G.F.; Agboola, K.M.; Oo, Y.H.; Mi, Z.; Pereira, T.A.; Zdanowicz, M.; Malladi, P. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011, 53, 106-115. [CrossRef] [PubMed]
69. Yang, Z.; Zhang, B.; Liu, B.; Xie, Y.; Cao, X. Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer. Tumor. Biol. 2015, 36, 4565-4573. [CrossRef] [PubMed]
70. Inman, C.K.; Shore, P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J. Biol. Chem. 2003, 278, 48684-48689. [CrossRef] [PubMed]
71. Shen, Q.; Christakos, S. The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J. Biol. Chem. 2005, 280, 40589-40598. [CrossRef] [PubMed]
72. Choi, S.S.; Claridge, L.C.; Jhaveri, R.; Swiderska-Syn, M.; Clark, P.; Suzuki, A.; Pereira, T.A.; Mi, Z.; Kuo, P.C.; Guy, C.D.; et al. Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. Clin. Sci. (Lond.) 2014, 126, 845-855. [CrossRef] [PubMed]
73. Iqbal, J.; McRae, S.; Mai, T.; Banaudha, K.; Sarkar-Dutta, M.; Waris, G. Role of hepatitis C virus induced osteopontin in epithelial to mesenchymal transition, migration and invasion of hepatocytes. PLoS ONE 2014, 9, e87464. [CrossRef] [PubMed]
74. Li, Y.; Liu, Y.; Xu, Y.; Voorhees, J.J.; Fisher, G.J. UV irradiation induces Snail expression by AP-1 dependent mechanism in human skin keratinocytes. J. Dermatol. Sci. 2010, 60, 105-113. [CrossRef] [PubMed]
75. Wynn, T.A.; Ramalingam, T.R. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 2012, 18, 1028-1040. [CrossRef] [PubMed]
76. Coombes, J.D.; Swiderska-Syn, M.; Dolle, L.; Reid, D.; Eksteen, B.; Claridge, L.; Briones-Orta, M.A.; Shetty, S.; Oo, Y.H.; Riva, A.; et al. Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. Gut 2015, 64, 1120-1131. [CrossRef] [PubMed]
77. Omenetti, A.; Porrello, A.; Jung, Y.; Yang, L.; Popov, Y.; Choi, S.S.; Witek, R.P.; Alpini, G.; Venter, J.; Vandongen, H.M.; et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J. Clin. Investig. 2008, 118, 3331-3342. [CrossRef] [PubMed]
78. Lenga, Y.; Koh, A.; Perera, A.S.; McCulloch, C.A.; Sodek, J.; Zohar, R. Osteopontin expression is required for myofibroblast differentiation. Circ. Res. 2008, 102, 319-327. [CrossRef] [PubMed]
79. Kohan, M.; Breuer, R.; Berkman, N. Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am. J. Respir. Cell Mol. Biol. 2009, 41, 290-296. [CrossRef] [PubMed]
80. Oh, K.; Seo, M.W.; Kim, Y.W.; Lee, D. Osteopontin Potentiates Pulmonary Inflammation and Fibrosis by Modulating IL-17/IFN--secreting T-cell Ratios in Bleomycin-treated Mice. Immune Netw. 2015, 15, 142-149. [CrossRef] [PubMed]
81. Pardo, A.; Gibson, K.; Cisneros, J.; Richards, T.J.; Yang, Y.; Becerril, C.; Yousem, S.; Herrera, I.; Ruiz, V.; Selman, M. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2005, 2. [CrossRef] [PubMed]
82. Friedman, S.L. Liver fibrosis-from bench to bedside. J. Hepatol. 2003, 38, 38-53. [CrossRef]
83. Ginès, P.; Cárdenas, A.; Arroyo, V.; Rodés, J. Management of cirrhosis and ascites. N. Engl. J. Med. 2004, 350, 1646-1654. [CrossRef] [PubMed]
84. Longo, D.L.; Rockey, D.C.; Bell, P.D.; Hill, J.A. Fibrosis-A Common Pathway to Organ Injury and Failure. N. Engl. J. Med. 2015, 372, 1138-1149. [CrossRef] [PubMed]
85. Leung, T.; Wang, X.; Kitamura, N.; Fiel, M.I.; Nieto, N. Osteopontin delays resolution of liver fibrosis. Lab. Investig. 2013, 93, 1082-1089. [CrossRef] [PubMed]
86. Takuwa, Y.; Ikeda, H.; Okamoto, Y.; Takuwa, N.; Yoshioka, K. Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases. Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids 2013, 1831, 185-192. [CrossRef] [PubMed]
87. Laufs, U.; Kilter, H.; Konkol, C.; Wassmann, S.; Bohm, M.; Nickenig, G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc. Res. 2002, 53, 911-920. [CrossRef]
88. Guarino, M.; Tosoni, A.; Nebuloni, M. Direct contribution of epithelium to organ fibrosis: Epithelialmesenchymal transition. Hum. Pathol. 2009, 40, 1365-1376. [CrossRef] [PubMed]
89. Okazaki, M.; Fushida, S.; Harada, S.; Tsukada, T.; Kinoshita, J.; Oyama, K.; Tajima, H.; Ninomiya, I.; Fujimura, T.; Ohta, T. The Angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Cancer Lett. 2014, 355, 46-53. [CrossRef] [PubMed]
90. Wan, J.; Zhou, X.; Cui, J.; Zou, Z.; Xu, Y.; You, D. Role of complement 3 in TNF-_-induced mesenchymal transition of renal tubular epithelial cells in vitro. Mol. Biotechnol. 2013, 54, 92-100. [CrossRef] [PubMed]
91. Adachi, T.; Arito, M.; Suematsu, N.; Kamijo-Ikemori, A.; Omoteyama, K.; Sato, T.; Kurokawa, M.S.; Okamoto, K.; Kimura, K.; Shibagaki, Y. Roles of layilin in TNF-_-induced epithelial-mesenchymal transformation of renal tubular epithelial cells. Biochem. Biophys. Res. Commun. 2015, 467, 63-69. [CrossRef] [PubMed]
92. Zavadil, J.; Böttinger, E.P. TGF-_ and epithelial-to-mesenchymal transitions. Oncogene 2005, 24, 5764-5774. [CrossRef] [PubMed]
93. Shi, Y.; Massagué, J. Mechanisms of TGF-_ signaling from cell membrane to the nucleus. Cell 2003, 113, 685-700. [CrossRef]
94. Saika, S.; Kono-Saika, S.; Ohnishi, Y.; Sato, M.; Muragaki, Y.; Ooshima, A.; Flanders, K.C.; Yoo, J.; Anzano, M.; Liu, C. Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am. J. Pathol. 2004, 164, 651-663. [CrossRef]
95. Flanders, K.C.; Wakefield, L.M. Transforming growth factor-_s and mammary gland involution; functional roles and implications for cancer progression. J. Mammary Gland Biol. Neoplasia 2009, 14, 131-144. [CrossRef] [PubMed]
96. Xiao, Z.; Zhang, J.; Peng, X.; Dong, Y.; Jia, L.; Li, H.; Du, J. The Notch -secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-_/Smad2/3 signaling pathway activation. Int. J. Biochem. Cell Biol. 2014, 55, 65-71. [CrossRef] [PubMed]
97. Chen, Y.; Zheng, S.; Qi, D.; Zheng, S.; Guo, J.; Zhang, S.; Weng, Z. Inhibition of Notch signaling by a -secretase inhibitor attenuates hepatic fibrosis in rats. PLoS ONE 2012, 7, e46512. [CrossRef] [PubMed]
98. Coward, W.; Deacon, K.; Pang, L. Activation Of Epidermal Growth Factor Receptor (EGFR) Is Required For Tgf_1-Induced Epithelial-Mesenchymal Transition (EMT) In Idiopathic Pulmonary Fibrosis (IPF). Am. J. Respir. Crit. Care Med. 2013, 187. [CrossRef]
99. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392-401. [CrossRef] [PubMed]
100. Kothari, A.N.; Mi, Z.; Zapf, M.; Kuo, P.C. Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clin. Transl. Med. 2014, 3, 14-35. [CrossRef] [PubMed]
101. Weber, C.; Kothari, A.; Wai, P.; Li, N.; Driver, J.; Zapf, M.; Franzen, C.; Gupta, G.; Osipo, C.; Zlobin, A. Osteopontin mediates an MZF1-TGF-_1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene 2014, 34, 4821-4833. [CrossRef] [PubMed]
102. Driver, J.; Weber, C.E.; Callaci, J.J.; Kothari, A.N.; Zapf, M.A.; Roper, P.M.; Borys, D.; Franzen, C.A.; Gupta, G.N.; Wai, P.Y.; et al. Alcohol inhibits osteopontin-dependent transforming growth factor-beta1 expression in human mesenchymal stem cells. J. Biol. Chem. 2015, 290, 9959-9973. [CrossRef] [PubMed]
103. Sharon, Y.; Raz, Y.; Cohen, N.; Ben-Shmuel, A.; Schwartz, H.; Geiger, T.; Erez, N. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res. 2015, 75, 963-973. [CrossRef] [PubMed]
104. Kojima, Y.; Acar, A.; Eaton, E.N.; Mellody, K.T.; Scheel, C.; Ben-Porath, I.; Onder, T.T.; Wang, Z.C.; Richardson, A.L.; Weinberg, R.A.; et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 2010, 107, 20009-20014. [CrossRef] [PubMed]
105. Yu, Y.; Xiao, C.; Tan, L.; Wang, Q.; Li, X.; Feng, Y. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-_ signalling. Br. J. Cancer 2014, 110, 724-732. [CrossRef] [PubMed]
106. Zhuang, J.; Lu, Q.; Shen, B.; Huang, X.; Shen, L.; Zheng, X.; Huang, R.; Yan, J.; Guo, H. TGF_1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT. Sci. Rep. 2015, 5. [CrossRef] [PubMed]
107. Nakano, M.; Ariyama, H.; Tamura, S.; Isobe, T.; Miyawaki, K.; Okumura, Y.; Kusaba, H.; Ueki, T.; Baba, E.; Akashi, K. Plasticity of CD44 colorectal cancer stem cells depends on TGF-beta-induced epithelial mesenchymal transition (EMT): Evidences from ex vivo culture system. Cancer Res. 2015, 75. [CrossRef]
108. Pore, M.M.; Buikema, L.; Hiltermann, T.; Kruyt, F. TGF beta-mediated epithelial to mesenchymal transition in non small cell lung cancer: Effects on stemness, invasiveness and chemotherapy sensitivity. Cancer Res. 2012, 72. [CrossRef]
109. Liu, F.; Kong, X.; Lv, L.; Gao, J. TGF-_1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer Lett. 2015, 359, 288-298. [CrossRef] [PubMed]
110. Su, L.; Wu, X.; Zhou, Q.; Wang, C.; Liu, B. Cancer-associated fibroblast promotes gastric cancer invasion and epithelial-mesenchymal transition via the IL-6/JAK/STAT3 signaling pathway. Cancer Res. 2014, 74. [CrossRef]
111. Nagasaki, T.; Hara, M.; Nakanishi, H.; Takahashi, H.; Sato, M.; Takeyama, H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: Anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br. J. Cancer 2014, 110, 469-478. [CrossRef] [PubMed]
112. Piera-Velazquez, S.; Li, Z.; Jimenez, S.A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. 2011, 179, 1074-1080. [CrossRef] [PubMed]
113. Guan, J.; Zhang, H.; Wen, Z.; Gu, Y.; Cheng, Y.; Sun, Y.; Zhang, T.; Jia, C.; Lu, Z.; Chen, J. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 2014, 345, 132-139. [CrossRef] [PubMed]
114. Sun, X.; Mao, Y.; Wang, J.; Zu, L.; Hao, M.; Cheng, G.; Qu, Q.; Cui, D.; Keller, E.; Chen, X. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene 2014. [CrossRef] [PubMed]